Icrucumab

CAS No. 1024603-92-6

Icrucumab( —— )

Catalog No. M36749 CAS No. 1024603-92-6

Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 511 In Stock
10MG 825 In Stock
25MG 1216 In Stock
50MG 1609 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Icrucumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.
  • Description
    Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1024603-92-6
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. LoRusso PM, et al. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11.?
molnova catalog
related products
  • Tyrosine kinase-IN-1

    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor(KDR Flt-1 FGFR1 and PDGFRα with IC50s of 4nM 20nM 4nM 2 nM respectively).

  • Bevacizumab

    Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high affinity.

  • 8-O-Acetylshanzhisid...

    8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppression of intracellular Ca2+ elevation and caspase-3 activity.